Sharecafe

Breakthrough results for INOVIQ’s ovarian cancer test

INOVIQ's recent validation study of its EXO-OC test revealed it can detect stage one ovarian cancer with 96% specificity and more than 90% sensitivity, a promising advance for early detection.
Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x

 

INOVIQ's recent validation study of its EXO-OC test revealed it can detect stage one ovarian cancer with 96% specificity and more than 90% sensitivity, a promising advance for early detection.

The company's breast cancer screen test has also demonstrated superior accuracy over current tests.

Serving up fresh finance news, marker movers & expertise.
LinkedIn
Email
X

All Categories